CORE: Cell Processing and Vector Production Shared Resource (Clinical Focus Group) PROJECT SUMMARY Cellular and gene therapies are finding more widespread use in the treatment of leukemias and solid tumors, and in repairing tissues that have been damaged by these diseases.The number of Phase 1 cell and gene therapy Investigational New Drug applications (INDs) submitted to the Food and Drug Administration (FDA) has undergone exponential growth. A potential barrier to conducting such studies is the FDA requirement that these biological drugs must be manufactured under current Good Manufacturing Practices (GMP) regulations. These provide a highly documented framework that specifies the conditions for manufacturing, testing, releasing and distributing the therapeutic product. The Cell Processing and Vector Production Shared Resource at the Baylor Center for Cell and Gene Therapies provides Dan L. Duncan Cancer Center (DLDCC) investigators with access to a highly experienced, state-of-the-art GMP facility consisting of 22 manufacturing clean rooms, product analytical services, and Quality Control laboratories and Quality Assurance services. In addition, the GMP staff have extensive experience manufacturing a wide range of cellular products and viral vectors. They are also very familiar with the submission of regulatory documents to support IND applications. This resource can speed the transition of cellular and gene therapy products from the basic science laboratory into early-phase clinical trials. Traditionally this translational step has been a major impediment to starting IND studies. Staff of this DLDCC resource will work with investigators to develop clinical scale manufacturing procedures, release test specifications, testing procedures, quality assurance oversight, and regulatory assistance to assist in IND submissions. They will then provide both the clinical products for the trial, and summary data for annual reports. This service places DLDCC researchers at a distinct advantage when transitioning from research studies to clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Boudreaux, Seth P; Duren, Ryan P; Call, Steven G et al. (2018) Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia :
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42
Ostrom, Quinn T; Kinnersley, Ben; Wrensch, Margaret R et al. (2018) Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep 8:7352
Chen, Fengju; Zhang, Yiqun; Varambally, Sooryanarayana et al. (2018) Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. Mol Cancer Res :
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Badr, Hoda; Herbert, Krista; Bonnen, Mark D et al. (2018) Dyadic Coping in Patients Undergoing Radiotherapy for Head and Neck Cancer and Their Spouses. Front Psychol 9:1780
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139

Showing the most recent 10 out of 991 publications